Positive preliminary results from first comparative study with the Episealer® Knee implant
Episurf Medical (Nasdaq: EPIS B) today announces promising results from the study with the title “X-ray fluoroscopic analysis of knee joint kinematic in open and closed chain activities in patients with Episealer Knee implants” performed at Charité University Hospital, Berlin. Preliminary results show good patient satisfaction and good knee function.
The Episealer® Knee implant is intended for treatment of focal cartilage and osteochondral defects on the femoral side of the knee joint. The Episealer® Knee implant is fully tailored to fit each patient’s unique curvature of the joint surface, the size and shape of the lesion, and underlying bone conditions.
The objective of this retrospective study is to measure the knee function of patients who received an Episealer® and compare with the knee function of patients who received a total knee prosthesis as well as with patients with healthy, untreated knees.
“Knee replacement surgery is a significant and definitive procedure that often does not produce a perfectly functioning knee. For example, range of motion seldom becomes normal due to lack of anatomic precision. Hence, a comparative functionality study on Episurf Medical’s individualised implant is valuable. Hypothetically, the Episealer® should result in better functionality, and this is the conclusion that these preliminary results are pointing towards. These results add to previously reported strong clinical results, such as pain and activity scores” says Prof. Leif Ryd, Senior Medical Advisor at Episurf Medical.
After recruitment and follow-up of 90% of the patients, the results are promising, showing good self-reported patient satisfaction (clinical questionnaires) as well as high passive and active knee joint flexion in line with the function of healthy, untreated knees. Preliminary qualitative analysis during the data processing shows an apparent physiological external rotation of the femur as well as signs of femoral rollback from extension until high flexion. Final quantitative analysis remains once all patients have been tested.
“This is the first comparative study with patients who have received Episealer® implants. We are very happy to hear that the preliminary results are in line with our expectations and that we actually restore the joint function”, says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 31 March 2020.
Tags: